The Dual PDE7-GSK3β Inhibitor, VP3.15, as Neuroprotective Disease-Modifying Treatment in a Model of Primary Progressive Multiple Sclerosis
Multiple sclerosis (MS) is a chronic, inflammatory, autoimmune and degenerative disease with axonal damage and demyelination as its main features. Its dual neurological and autoimmune nature makes it a disease that is difficult to treat. Treatments that simultaneously stop the immune response while...
Main Authors: | Rocio Benítez-Fernández, Carmen Gil, Carmen Guaza, Leyre Mestre, Ana Martínez |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-11-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/23/22/14378 |
Similar Items
-
High throughput method for detecting murine brain atrophy using a clinical 3T MRI
by: Michael Linzey, et al.
Published: (2023-11-01) -
Theiler’s virus-induced demyelinating disease as an infectious model of progressive multiple sclerosis
by: Steven C. Pike, et al.
Published: (2022-10-01) -
GSK3α: An Important Paralog in Neurodegenerative Disorders and Cancer
by: Octavio Silva-García, et al.
Published: (2020-12-01) -
GSK-3 and Tau: A Key Duet in Alzheimer’s Disease
by: Carmen Laura Sayas, et al.
Published: (2021-03-01) -
Role of Phosphodiesterase 7 (PDE7) in T Cell Activity. Effects of Selective PDE7 Inhibitors and Dual PDE4/7 Inhibitors on T Cell Functions
by: Marianna Szczypka
Published: (2020-08-01)